Ophthalmology: Recent Episodes
ReachMD
Saving Sight, and Preventing Vision Loss in Diabetic Retinopathy and Diabetic Macular Edema: Ophthalmology Learning Path
Host: Prem S. Subramanian, MD, PhD
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Guest: Terry J. Smith, MD
Guest: Selina McGee, OD, FAAO
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Guest: Selina McGee, OD, FAAO
Guest: Terry J. Smith, MD
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Guest: Fatemeh Rajaii, MD, PhD
Guest: Terry J. Smith, MD
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Host: Prem S. Subramanian, MD, PhD
Guest: Selina McGee, OD, FAAO
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Host: Prem S. Subramanian, MD, PhD
Guest: Fatemeh Rajaii, MD, PhD
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Host: Prem S. Subramanian, MD, PhD
Guest: Terry J. Smith, MD
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Guest: Fatemeh Rajaii, MD, PhD
Guest: Selina McGee, OD, FAAO
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Guest: Fatemeh Rajaii, MD, PhD
Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.
Host: Diana V. Do, MD
Guest: Peter K. Kaiser, MD
This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.
Host: Arshad M. Khanani, MD, MA
Guest: Karl Csaky, MD, PhD
Guest: Christina Y. Weng, MD, MBA, FASRS
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.
Host: Carl Regillo, MD
Guest: Jennifer I. Lim, MD, FARVO
What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neovascular age-related macular degeneration and diabetic macular edema.
Host: Arshad M. Khanani, MD, MA
Guest: Theodore Leng, MD, MS
Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.
Guest: Durga Borkar, MD, MMCi
Guest: Diana Do, MD
Guest: Peter K. Kaiser, MD
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.
Guest: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professor at the University of Nevada in Reno, Nevada, will present key data about anti-VEGF therapies for retinal vein occlusion (RVO). Join the discussion on developing treatment protocols that use current therapies most effectively to improve outcomes and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.
Guest: Cara Dolin, MD
Guest: Jennifer Simpson
Guest: Diana Girnita, MD ,PhD
Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.
Host: Christina Y. Weng, MD, MBA, FASRS
Host: Durga Borkar, MD, MMCi
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Jayanth Sridhar, MD
Host: Sabin Dang, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Durga Borkar, MD, MMCi
Host: Christina Y. Weng, MD, MBA, FASRS
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Christina Y. Weng, MD, MBA, FASRS
Host: Durga Borkar, MD, MMCi
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Sabin Dang, MD
Host: Jayanth Sridhar, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Sabin Dang, MD
Host: Jayanth Sridhar, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Jayanth Sridhar, MD
Host: Sabin Dang, MD
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Durga Borkar, MD, MMCi
Host: Christina Y. Weng, MD, MBA, FASRS
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Christina Y. Weng, MD, MBA, FASRS
Host: Durga Borkar, MD, MMCi
The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Mark Pennesi, MD, PhD
Approximately 165,700 people in the United States are affected by inherited retinal diseases (IRDs) and treatment options for these conditions are limited. So what role does genetic testing play in the patient journey of people living with IRDs? Join Dr. Charles Turck as he dives into this topic with Dr. Mark Pennesi, Professor of Ophthalmology and an IRD specialist affiliated with the Casey Eye Institute at the Oregon Health and Science University School of Medicine.
©Janssen Pharmaceuticals, Inc. 2023 05/23 cp-367503v1
Host: Neda Shamie, MD
Guest: Marguerite McDonald, MD, FACS
Marguerite McDonald, MD, FACS, and Neda Shamie, MD, discuss a literature review and panel discussion that sought to develop a consensus statement on the classification of presbyopia by severity. What were the results?
Host: Neda Shamie, MD
Guest: Julie Schallhorn, MD
Julie Schallhorn, MD, joins Neda Shamie, MD, to discuss a review conducted by the AAO of the published literature on the safety and efficacy of presbyopia-correcting IOLs available in the United States. Learn more about the findings.
Host: Neda Shamie, MD
Guest: Inder Paul Singh, MD
Inder Paul Singh, MD, sits down with Neda Shamie, MD, to discuss a retrospective analysis that evaluated the Medicare claims–based 5-year economic and reintervention burden for patients with primary open-angle glaucoma after incisional glaucoma surgery in the United States. What do the findings suggest for clinical and surgical practice?
Host: Neda Shamie, MD
Guest: Jay S. Pepose, MD, PhD
Jay S. Pepose, MD, PhD, sits down with Neda Shamie, MD, to talk about a phase 3 multicenter, randomized, placebo-controlled, double-masked clinical trial that evaluated the safety and efficacy of 0.75% phentolamine ophthalmic solution for the reversal of pharmacologically induced mydriasis. What were the findings of the MIRA-2 study?
Host: Neda Shamie, MD
Guest: Cynthia Matossian, MD
Cynthia Matossian, MD, joins Neda Shamie, MD, to discuss a national, noninterventional, cross-sectional, mixed methods survey that evaluated cataract surgery candidates’ knowledge and emotions as they related to cataract surgery and their behavioral intent to adhere to a doctor-recommended presurgical ocular surface prep routine. Learn more about commonly held assumptions.
Host: Neda Shamie, MD
Guest: Kendall Donaldson, MD
Kendall Donaldson, MD, sits down with Neda Shamie, MD, to discuss a retrospective chart review in which investigators evaluated the refractive outcomes of phacoemulsification in eyes with Fuchs endothelial corneal dystrophy. Did results differ between eyes that underwent laser cataract surgery and those that received conventional phacoemulsification?
Host: Neda Shamie, MD
Guest: Francis Mah, MD
Francis Mah, MD, joins Neda Shamie, MD, to discuss a post hoc analysis of data from a phase 3 evaluation of the safety of netarsudil 0.02% compared to timolol 0.5%. Learn the results.
Host: Neda Shamie, MD
Guest: Jason Bacharach, MD
Jason Bacharach, MD, sits down with Neda Shamie, MD, to discuss a randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial that evaluated the IOP-lowering efficacy and safety of the bimatoprost implant (Durysta, Allergan) in patients with open-angle glaucoma or ocular hypertension. What were the results?
Host: Neda Shamie, MD
Guest: Brandon D. Ayres, MD
Brandon D. Ayres, MD, joins Neda Shamie, MD, to discuss an FDA clinical trial that evaluated the safety and efficacy of a custom-manufactured artificial iris device (CustomFlex ArtificialIris, HumanOptics) for the treatment of congenital and acquired iris defects. Learn the results.
Host: Charles P. Vega, MD
Guest: Pradeep S. Prasad, MD, MBA
Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.
Host: Charles P. Vega, MD
Guest: Sharon D. Solomon, MD
New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who are less likely to access routine healthcare. Tune in to hear Dr. Sharon Solomon and Dr. Charles Vega discuss how the latest clinical data measure up by prolonging treatment intervals and how retina specialists are now better equipped to care for their most vulnerable patients with DME.
Host: Charles P. Vega, MD
Guest: Ruth Shoge, OD, MPH, FAAO
Racial and ethnic minorities are disproportionately affected by diabetic eye disease, which is one of the leading causes of vision loss in the United States. Hear how Dr. Ruth Shoge and Dr. Charles Vega are approaching patient care and find out what tools are available to you. Join us in overcoming barriers to vision care so that all patients can receive the treatment they need.
Guest: Qi Cui, MD, PhD
First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.
Host: Rishi P. Singh, MD
Host: Mark R. Barakat, MD
Host: Arshad M. Khanani, MD, MA
Host: Christina Y. Weng, MD, MBA
This program will focus on the clinical trial and real-world data about the novel and emerging therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema and how these therapies may be integrated into real-world clinical practice.
Host: Jennifer Caudle, DO
Guest: Stefanie Cribb, PharmD
Guest: Ryan Haumschild, PharmD
Guest: Jennifer Rubin
Guest: Ira Steinberg, MD
There’s been a lot of focus recently on biosimilars and their potential role in evolving the healthcare system. We're digging in deeper to understand what makes biosimilars so exciting. Joining Dr. Jennifer Caudle to discuss the biosimilar approval process and the important commitment supporting healthcare providers and patients in their adoption is a panel of experts: Dr. Stefanie Cribb, Dr. Ira Steinberg, and Ms. Jennifer Rubin from Coherus Biosciences and Dr. Ryan Haumschild from the Emory Healthcare and Winship Cancer Institute.
© 2022 Coherus BioSciences
C1122-COH-P829
Host: Mario R. Nacinovich, Jr., MSc
Guest: Sally L. Baxter, MD, MSc
The All of Us Research Program discovered associations between socioeconomic factors and visit adherence among patients with glaucoma. Can clinicians use this data to improve visit adherence? Mario Nacinovich joins Dr. Sally Baxter, an Assistant Professor of Ophthalmology and Biomedical Informatics at the University of California-San Diego, to take a look at this data.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Sally L. Baxter, MD, MSc
The All of Us Research Program discovered how socioeconomic factors such as lower income and education levels were associated with lower odds of seeing an eye doctor. Mario Nacinovich joins Dr. Sally Baxter, an Assistant Professor of Ophthalmology and Biomedical Informatics at the University of California-San Diego, to explore how socioeconomic factors could impact care for patients with glaucoma.
Host: Christina Y. Weng, MD, MBA
Guest: Sophie J. Bakri, MD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Sophie J. Bakri, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Bakri also converse about the latest data on pipeline therapies for diabetic macular edema, including brolucizumab & PDS.
Host: Christina Y. Weng, MD, MBA
Guest: David Eichenbaum, MD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and David A Eichenbaum, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Eichenbaum also converse about the latest data on pipeline therapies for diabetic macular edema, including faricimab, KSI-301, and OPT-302.
Host: Christina Y. Weng, MD, MBA
Guest: Glenn Yiu, MD, PhD
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Glenn Yiu, MD, PhD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Yiu also converse about the latest data on pipeline therapies for diabetic macular edema, including high-dose aflibercept & gene therapy.
Host: Christina Y. Weng, MD, MBA
Guest: Basil K. Williams Jr, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Basil K. Williams Jr, MD, review details of a patient with wet age-related macular degeneration treated during the COVID-19 pandemic. This case highlights the need for increased durability of treatment options.
Drs. Weng and Williams also discuss the latest data on two investigational anti-VEGFs: an antibody biopolymer conjugate and a pan-VEGF plus placental growth factor inhibitor.
Host: Christina Y. Weng, MD, MBA
Guest: Diana Do, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Diana V. Do, MD, review pipeline therapies for wet age-related macular degeneration. Drs. Do and Weng assess challenging cases and focus specifically on how specific investigative therapies that target VEGF-A, C and D may have the potential to extend treatment intervals.
Host: Christina Y. Weng, MD, MBA
Guest: Peter A. Campochiaro, MD
In this video case discussion, Program Chair Christina Y. Weng, MD, MBA, and Peter A. Campochiaro, MD, review pipeline therapies for wet age-related macular degeneration. The faculty review challenging cases that would have potentially different outcomes with investigative therapies such as gene therapy and a novel, long-acting drug delivery system.
Host: Jillian Ziemanski, OD, PhD, FAAO
Guest: Cynthia Matossian, MD, FACS
How can more advanced measures improve meibomian gland function to relieve dry eye symptoms and improve refraction? Listen as Dr. Cynthia Matossian and Dr. Jillian Ziemanski discuss additional approaches you can try with your patients.
Host: Roger A. Goldberg, MD
Guest: Peter A. Campochiaro, MD
Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr. Peter Campochiaro and Dr. Roger Goldberg as they discuss ways these new approaches could benefit even more patients.
Host: Roger A. Goldberg, MD
Guest: Peter A. Campochiaro, MD
Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr. Peter Campochiaro and Dr. Roger Goldberg as they discuss ways these new approaches could benefit even more patients.
Host: Christina Y. Weng, MD, MBA
Guest: Margaret A. Chang, MD, MS
What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.
Host: Christina Y. Weng, MD, MBA
Guest: Margaret A. Chang, MD, MS
What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.
Host: David Eichenbaum, MD
Guest: Mark R. Barakat, MD
Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and Dr. Mark Barakat as they discuss patient management approaches based on the latest clinical data.
Host: David Eichenbaum, MD
Guest: Mark R. Barakat, MD
Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and Dr. Mark Barakat as they discuss patient management approaches based on the latest clinical data.
Host: John Kitchens, MD
Guest: SriniVas R. Sadda, MD
Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery technology into your clinical practice? Join Dr. SriniVas Sadda and Dr. John Kitchens as they discuss how the PDS fits into our treatment arsenal.
Host: John Kitchens, MD
Guest: SriniVas R. Sadda, MD
Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery technology into your clinical practice? Join Dr. SriniVas Sadda and Dr. John Kitchens as they discuss how the PDS fits into our treatment arsenal.
Host: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Carl Danzig as they discuss their approach to treatment based on the latest clinical evidence.
Host: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Carl Danzig as they discuss their approach to treatment based on the latest clinical evidence.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Yannis Paulus, MD, FACS
Early diagnosis of retinal diseases can make quite a difference when it comes to preserving our patients’ vision. But what are the symptoms we should be looking out for, and how can we optimize screening opportunities with our patients? Find out with Dr. Charles Turck as he explores effective strategies for detecting and treating retinal diseases early with Dr. Yannis Paulus from the University of Michigan Kellogg Eye Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Caroline Baumal, MD
Guest: Carl Regillo, MD
Multiple new and novel strategies are now available to treat patients with neovascular age-related macular degeneration and diabetic macular edema. What are these strategies, and how should they be used in everyday practice? Hear Dr. Caroline Baumal and Dr. Carl Regillo discuss the latest data and how they are adopting these new approaches into their retina patient care.
Host: Diana Do, MD
Guest: John A. Wells, III, MD
Second-generation intravitreal agents that incorporate new pathogenic targets have emerged for the treatment of retinal diseases. What are these targets, and how should these new medicines be used in clinical practice? Join Dr. Diana Do and Dr. John Wells as they discuss novel mechanisms for therapeutic control of neovascular age-related macular degeneration and diabetic macular edema and how to incorporate these new agents into clinical practice.
Host: J. Fernando Arevalo, MD, PhD
Guest: W. Lloyd Clark, MD
New technology has arrived that provides prolonged delivery of anti-VEGF therapy and with it comes new techniques for vitreoretinal surgeons. Find out what steps you need to take to ensure both successful implantation and refill-exchange of the port delivery system. Dr. Fernando Arevalo discusses these critical details with Dr. W. Lloyd Clark, one of the leading pioneers of this technology.
Host: Adrienne W. Scott, MD
Guest: Rajendra Apte, MD, PhD
Guest: Jennifer I. Lim, MD, FARVO
A main goal in the treatment of diabetic retinopathy is to intervene early enough to prevent vision loss. New data are giving us new tools for our armamentarium and helping us define what constitutes “early”—and if there’s such a thing as “too early.” Join us to take a closer look at the data surrounding the management of NPDR and CI-DME with good vision and hear our panelist of experts explain how the data translate into clinical care.
Host: Rahul N. Khurana, MD
Guest: Jennifer K. Sun, MD, MPH
The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?
Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.
Host: Ruth S. Weinstock, MD, PhD
Guest: Susan B. Bressler, MD
Guest: Mark Dunbar, OD, FAAO
With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?
Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.
Host: Jayanth Sridhar, MD
Guest: Avni P. Finn, MD, MBA
Are you aware of the latest data that adds to our understanding of the management of diabetic retinopathy (DR)? Listen in as Dr. Avni Finn and Dr. Jay Sridhar discuss what those data are and the impact they have on the early referral and timely treatment of patients with DR. Make sure you’re properly using all of the resources in your armamentarium to save your patients’ sight.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Carl C. Awh, MD
Guest: Peter A. Campochiaro, MD
The quest for durable VEGF-suppression in neovascular AMD and diabetic macular edema has led to significant advances in the operating room for surgical retina specialists. What are these new methods, and what do surgeons need to know to ensure a successful procedure? Listen to pro tips from Drs. Carl Awh and Peter Campochiaro and see demonstrations of the new techniques. How will your patients benefit from the introduction of durable VEGF suppression into clinical practice?
Host: Diana Do, MD
Guest: Nancy M. Holekamp, MD
Guest: Carl Regillo, MD
One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?
Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.
Host: Diana Do, MD
Guest: Nancy M. Holekamp, MD
Guest: Carl Regillo, MD
One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?
Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.
Host: Carl C. Awh, MD
Guest: Peter A. Campochiaro, MD
The quest for durable VEGF-suppression in neovascular AMD and diabetic macular edema has led to significant advances in the operating room for surgical retina specialists. What are these new methods, and what do surgeons need to know to ensure a successful procedure? Listen to pro tips from Drs. Carl Awh and Peter Campochiaro and see demonstrations of the new techniques. How will your patients benefit from the introduction of durable VEGF suppression into clinical practice?
Host: Christina Y. Weng, MD, MBA
Guest: Arshad M. Khanani, MD, MA
Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.
Host: Christina Y. Weng, MD, MBA
Guest: Arshad M. Khanani, MD, MA
Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.
Host: Vivian Fonseca, MD, FRCP
Guest: Rishi P. Singh, MD
Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.
Host: Vivian Fonseca, MD, FRCP
Guest: Rishi P. Singh, MD
Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.
Guest: David Eichenbaum, MD
Guest: Charles Wykoff, MD, PhD
Current challenges in the treatment of neovascular retinal disease include the tremendous burden of treatment and suboptimal response to treatment in many cases. Strides have been made recently toward therapies that deliver increased efficacy vs traditional first-line therapies, a decreased treatment burden, or both. To achieve these ends, next-generation treatment strategies target multiple angiogenic cellular pathways at once. In this activity, experts in retinal disease treatment use custom animations to discuss the mechanisms of action of various novel treatment strategies. The latest clinical trial data for faricimab and OPT-302, two molecules currently in phase 3 clinical trials for the treatment of retinal disease, are also presented.
Host: Emily Chew, MD
Guest: Neil Bressler, MD
Guest: Joseph M. Coney, MD
Guest: Steven Ferrucci, OD, FAAO
Approximately 2 million individuals in the United States are living with age-related macular degeneration (AMD), and another 1.6 million are living with retinal vein occlusion (RVO). These numbers are increasing daily due to an aging population and prevalence of risk factors. There have been many advances in treatment, but what else can you be doing to prevent vision loss in your patients?
In this activity, Dr. Emily Chew speaks with Drs. Neil Bressler, Joseph Coney, and Steven Ferrucci to examine the evidence around early diagnosis, referral, and treatment of AMD and RVO and the impact of these diseases on patients’ lives.
Host: Michael S. Ip, MD
Guest: Christina Y. Weng, MD, MBA
For patients with retinal vascular disease, time is vision. But there are key components that can help you diagnose early neovascular age-related macular degeneration and retinal vein occlusion before permanent vision loss occurs. Drs. Michael Ip and Christina Weng discuss warning signs, risk factors for progression, and the steps you can take to ensure early diagnosis and improved outcomes for your patients.
Host: Diana Do, MD
Guest: Julia Haller, MD
Guest: Rishi P. Singh, MD
Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in patients with neovascular AMD, but what else can we do to maximize long-term vision in these patients? Drs. Do, Haller, and Singh discuss the key role of fluid in the treatment of wet AMD, dosing interval data from clinical trials, and the importance of patient expectations when selecting therapy.
Host: Adrienne W. Scott, MD
Guest: Peter A. Campochiaro, MD
Guest: Rahul N. Khurana, MD
Retinal vein occlusion (RVO) can lead to macular edema, which is the main cause of vision loss. Accordingly, retina specialists know that time is vision and prompt intervention is critical to good outcomes in patients with RVO.
Join our discussion with Drs. Campochiaro, Khurana, and Scott to discover strategies to use with your patients before and during treatment and throughout maintenance to improve visual acuity while minimizing side effects.
Host: Diana Shechtman, OD, FAAO
Guest: Mark T. Dunbar, OD, FAAO
Early diagnosis and early treatment of age-related macular degeneration (AMD) and retinal vein occlusion (RVO) can be critical to preserving a patient’s vision. How can optometrists, who are on the frontlines of eye care, diagnose and refer patients early in the disease process to ensure the best visual outcomes for patients? Join the discussion with Dr. Dunbar and Dr. Shechtman to find out more about how time is vision for these patients.
Host: Peter K. Kaiser, MD
Guest: Dante J. Pieramici, MD
Correctly identifying retinal diseases early on is essential in preserving your patients’ vision. How do physicians distinguish key pathological features to identify early neovascular age-related macular degeneration (AMD) and retinal vein occlusion (RVO) before macular edema leads to permanent vision loss?
In this activity, Drs. Kaiser and Pieramici discuss these key pathologies in AMD and RVO and when further evaluation with advanced imaging is necessary—for these patients, time is vision.
Host: Neil Bressler, MD
Hear the world-renowned Dr. Neil Bressler discuss the important role you can play in saving vision when wet AMD strikes.
###### Scroll down to download our Wet AMD handout, so you can share it with your patients! The handout includes a QR code where patients can access this video.
Host: Peter K. Kaiser, MD
Guest: Dante J. Pieramici, MD
Correctly identifying retinal diseases early on is essential in preserving your patients’ vision. How do physicians distinguish key pathological features to identify early neovascular age-related macular degeneration (AMD) and retinal vein occlusion (RVO) before macular edema leads to permanent vision loss?
In this activity, Drs. Kaiser and Pieramici discuss these key pathologies in AMD and RVO and when further evaluation with advanced imaging is necessary—for these patients, time is vision.
Host: Emily Chew, MD
Guest: Neil Bressler, MD
Guest: Joseph M. Coney, MD
Guest: Steven Ferrucci, OD, FAAO
Approximately 2 million individuals in the United States are living with age-related macular degeneration (AMD), and another 1.6 million are living with retinal vein occlusion (RVO). These numbers are increasing daily due to an aging population and prevalence of risk factors. There have been many advances in treatment, but what else can you be doing to prevent vision loss in your patients?
In this activity, Dr. Emily Chew speaks with Drs. Neil Bressler, Joseph Coney, and Steven Ferrucci to examine the evidence around early diagnosis, referral, and treatment of AMD and RVO and the impact of these diseases on patients’ lives.
Host: Adrienne W. Scott, MD
Guest: Peter A. Campochiaro, MD
Guest: Rahul N. Khurana, MD
Retinal vein occlusion (RVO) can lead to macular edema, which is the main cause of vision loss. Accordingly, retina specialists know that time is vision and prompt intervention is critical to good outcomes in patients with RVO.
Join our discussion with Drs. Campochiaro, Khurana, and Scott to discover strategies to use with your patients before and during treatment and throughout maintenance to improve visual acuity while minimizing side effects.
Host: Michael S. Ip, MD
Guest: Christina Y. Weng, MD, MBA
For patients with retinal vascular disease, time is vision. But there are key components that can help you diagnose early neovascular age-related macular degeneration and retinal vein occlusion before permanent vision loss occurs. Drs. Michael Ip and Christina Weng discuss warning signs, risk factors for progression, and the steps you can take to ensure early diagnosis and improved outcomes for your patients.
Host: Diana Shechtman, OD, FAAO
Guest: Mark T. Dunbar, OD, FAAO
Early diagnosis and early treatment of age-related macular degeneration (AMD) and retinal vein occlusion (RVO) can be critical to preserving a patient’s vision. How can optometrists, who are on the frontlines of eye care, diagnose and refer patients early in the disease process to ensure the best visual outcomes for patients? Join the discussion with Dr. Dunbar and Dr. Shechtman to find out more about how time is vision for these patients.
Host: Diana Do, MD
Guest: Julia Haller, MD
Guest: Rishi P. Singh, MD
Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in patients with neovascular AMD, but what else can we do to maximize long-term vision in these patients? Drs. Do, Haller, and Singh discuss the key role of fluid in the treatment of wet AMD, dosing interval data from clinical trials, and the importance of patient expectations when selecting therapy.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: William Tarver, MD
Guest: Tyson Brunstetter, PhD, MBA
Since 2012, at least 27 astronauts have been diagnosed with spaceflight-associated neuro-ocular syndrome, but where does this health threat land now? Joining Dr. Andrew Wilner to discuss this out-of-this-world health threat is Captain Tyson Brunsteller and Dr. William Tarver from NASA.
Host: Jennifer Caudle, DO
Guest: Anne Negrin, MD
Since eye issues are becoming increasingly common in patients with rheumatological conditions, it’s now more vital than ever that physicians are aware of their common symptoms. Joining Dr. Jennifer Caudle is Dr. Anne Negrin, an ophthalmologist in New York, to break down these symptoms and to focus on rheumatological concerns that ophthalmologists see in practice.
Host: Jennifer Caudle, DO
Guest: Jean Bennett, MD, PhD
Guest: Albert Maguire, MD
Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership.
Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children’s Hospital of Philadelphia.
Guest: David S. Friedman, MD, PhD, MPH
Guest: Steven J. Gedde, MD
Guest: W. Daniel Stamer, PhD
THIS ACTIVITY IS NO LONGER AVAILABLE FOR CREDIT.
Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.
In this CME/CE-certified enduring activity, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice. These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; …
Guest: David S. Friedman, MD, PhD, MPH
Guest: Steven J. Gedde, MD
Guest: W. Daniel Stamer, PhD
THIS ACTIVITY IS NO LONGER AVAILABLE FOR CREDIT.
Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.
In this CME/CE-certified enduring activity, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice. These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; …
Host: Shira Johnson, MD
Guest: Jean Bennett, MD, PhD
There are 39 million people worldwide who are in total blindness and another 246 million with very low vision. The most frequent forms of visual impairment are caused by problems that can be corrected. Dr. Shira Johnson welcomes Dr. Jean Bennett, Professor of Ophthalmology and Cell and Developmental Biology at the University of Pennsylvania and researcher at the Children’s Hospital of Philadelphia. Dr. Bennett discusses her innovative work and research in curing blindness through gene therapy.
Host: Shira Johnson, MD
Guest: Jean Bennett, MD, PhD
There are 39 million people worldwide who are in total blindness and another 246 million with very low vision. The most frequent forms of visual impairment are caused by problems that can be corrected. Dr. Shira Johnson welcomes Dr. Jean Bennett, Professor of Ophthalmology and Cell and Developmental Biology at the University of Pennsylvania and researcher at the Children’s Hospital of Philadelphia. Dr. Bennett discusses her innovative work and research in curing blindness through gene therapy.
Host: Maurice Pickard, MD
Guest: Rebecca Alexander
Born with a rare genetic mutation called Usher Syndrome type III, Rebecca Alexander has been simultaneously losing both her sight and hearing since she was a child, and was told that she would likely be completely blind and deaf by age 30. Then, at 18, a fall from a window left her athletic body completely shattered.
In Not Fade Away, Rebecca tells her extraordinary story, by turns harrowing, funny and inspiring. She meditates on what she’s lost—from the sound of a whisper to seeing a sky full of stars, and what she’s found in return—an exquisite sense of intimacy with those she is closest to, a love of silence, a profound gratitude for everything she still has, and a joy in simple pleasures that most of us forget to notice.
[Read the Article]
Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the procedure has many side effects including permanent loss of peripheral vision and swelling of the retina.
A group of researchers from across the US tested an alternative treatment using an injectable medication called ranibizumab, to see if it would be as effective as the laser therapy. They studied more than 300 patients with PDR, assigning them to either receive standard laser therapy or an injection into the eye. In total, they treated close to 400 eyes.
Outcomes, especially loss of vision, were compared at two years. Over the two year period, researchers found that patients receiving the injections of medication had fewer side effects and did somewhat better in terms of vision loss than those who received laser therapy.
[Watch more videos of The JAMA Report]
Host: Jennifer Caudle, DO
Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Dr. Gail L. Torkildsen, staff ophthalmologist at Andover Eye Associates and one of the leading Dry Eye Principal Investigators in the world. Dr. Torkildsen has served as P.I. on over 20 client-sponsored Dry Eye studies since 2002. In this discussion she takes listeners on a tour of common eye problems faced in primary care, and how clinicians can better prepare themselves to address issues such as Meibobian gland disorders, blepharitis, dry eyes, and conjunctivitis with greater confidence.
Host: Brian P. McDonough, MD, FAAFP
A clinical pearl in the arena of eye care is that serious eye problems tend to manifest serious symptoms and signs, which makes vision loss one of the key findings in a diagnostic workup. Yet vision testing is commonly neglected in primary care practice even when patients present with eye-related complaints. What are the most important steps a clinician can take when assessing eye problems, and where does the primary care practitioner fit into the ophthalmologic care continuum? Dr. Brian McDonough welcomes Dr. Sumitra Khandelwal, Assistant Professor of Ophthalmology at Baylor College of Medicine, to examine the top issues in eye care for generalists and ophthalmic specialists.
Host: Brian P. McDonough, MD, FAAFP
On average, more than 90% of adults spend more than two hours each day using a digital device, and for 60% of the population, that daily use pattern extends beyond five hours. Regardless of the reasons why, all that time can take a toll on the eyes and lead to digital eye strain. Speaking on the health implications of digital eye strain is Dr. Dora Adamopolous, optometrist in practice in Alexandia, VA.
Guest: Lee Philip Shulman, MD, FACOG, FACMG
Omnia Education's and Prova Education's combined Capstone Conference in New York took advantage of common interests across all learners, addressing clinical trends and future directions across a broad spectrum of primary care and women's health topics. Joining host Lawrence Sherman to reflect on highlights from the combined agenda of Omnia's Stages in Women's Health® and Prova's Evolving Practice of Primary CareTM is Dr. Lee Shulman, Professor of Obstetrics and Gynecology at Northwestern University's Feinberg School of Medicine and Chairman of the conference program.
Guest: Stephen Orlin, MD
This Excerpt from the Podium features Dr. Stephen Orlin, Associate Professor of Ophthalmology at the University of Pennsylvania School of Medicine, speaking on the patient workup for red eye at Prova Education's "From Guidelines to Practice" program in New York City.
Guest: Stephen Orlin, MD
The classic "red eye" presentation by your patient may be a common sighting in your clinical practice, but are you truly up to date on the various causes, treatments, and pitfalls that clinicians encounter when confronting ocular problems? Discussing this issue is Dr. Stephen Orlin, Associate Professor of Ophthalmology, Director of the Cornea Department, and Co-Director of the Refractive Surgery Service at the University of Pennsylvania.
Host: Lee Freedman, MD
Guest: Jean Bennett, MD, PhD
Host Dr. Lee Freedman and Dr. Jean Bennett, the FM Kirby Professor of Epistemology at the University of Pennsylvania School of Medicine, explore how the study of molecular genetics of inherited retinal degenerations can help develop treatments for congenital eye disorders, as well as adult-onset diseases and possibly disorders that affect the body outside the eye.
Host: Steven Edelman, MD
Guest: Azza El-Remessy, PhD, RPh
Retinopathy is one of the most common complications for patients living with diabetes but there are few treatment options and no early-stage interventions. How is research helping to pinpoint potential targets for early intervention and a possible oral treatment? Join host Dr. Steven Edelman and his guest, assistant professor and director of clinical and experimental therapeutics at the University of Georgia, Dr. Azza El-Remessy, as they discuss the latest research into the potential of statins to prevent diabetic-related blindness.
Host: Roy Levit, MD
Guest: Saad Shaikh, MD
Although floaters in one's vision are common, this symptom can be a key indicator of a retinal tear or detachment. What is the incidence of retinal detachment in the U.S., and when should a primary care physician suspect this condition? Dr. Saad Shaikh, associate professor and member of the teaching faculty at the University of Central Florida College of Medicine in Orlando, and assistant professor at the University of South Florida, College of Medicine and at the Florida State College of Medicine, discusses the development of retinal detachments, risk factors, and the techniques used to correct the condition. Dr. Roy Levit hosts.
Host: Roy Levit, MD
Guest: Allen Verne, MD
What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.
Host: Steven Edelman, MD
Guest: Paul Tornambe, MD
Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. Join host Dr. Steven Edelman and his guest, ophthalmologist Dr. Paul Tornambe, an instructor in the departments of ophthalmology and family practice at the University of California, San Diego, as they discuss early diagnosis, tele-health and the exciting new VEGF inhibitors treatment of diabetic macular edema.
Host: Jennifer Shu, MD, FAAP
Guest: David Abramson, MD
Survival rates for retinoblastoma now approach 100 percent, but in years past, enucleation was the only sure way to cure this rare pediatric malignancy. We're now seeing advances in chemotherapy that not only spare the child's eye, but can preserve vision as well. What makes this chemotherapy regimen so effective, and how can we build on its effectiveness to enhance the vision and the livelihood of children affected by retinoblastoma? Dr. David Abramson, chief of the ophthalmic oncology service at Memorial Sloan-Kettering Cancer Center in New York, joins host Dr. Jennifer Shu to talk about the breadth of retinoblastoma research that has helped us take important strides toward remediation of this disease.
Host: Lee Freedman, MD
Guest: Frederick Vivino, MD
Sjogren's syndrome is a commonly overlooked autoimmune disorder. Dry eyes and whole-body dryness are just two of the symptoms of Sjogren's syndrome that can suggest other conditions as well. How does Sjogren's present itself beyond dry eyes, and how severe is the condition? Dr. Frederick Vivino, clinical associate professor of medicine at the University of Pennsylvania School of Medicine, describes some of the tests and therapies available for Sjogren's syndrome to host Dr. Lee Freedman.
Produced in Cooperation with
Host: Roy Levit, MD
Guest: Allen Ho, MD
What are macular holes and macular pucker, and how do we treat these conditions? Host Dr. Roy Levit welcomes Dr. Allen Ho, professor of ophthalmology and an attending surgeon in the Retina Service at the Wills Eye Institute in Philadelphia, to discuss back-of-the-eye vitrectomy for the treatment of macular hole and macular pucker. Before this surgical procedure, we had no cure for these diagnoses.
Host: Bruce Bloom, DDS, JD
Guest: Mary Elizabeth Hartnett, MD
Almost a third of all type I and type II diabetics develop macular edema. Join host Dr. Bruce Bloom and his guest, ophthalmologist, researcher and vitreo-retinal surgeon Dr. Mary Elizabeth Hartnett, professor of opthamology at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the etiology and treatment of diabetic macular edema.
Host: Roy Levit, MD
Guest: Mark Humayun, MD
Microelectronic implants are restoring vision to the blind.Dr. Mark Humayun discusses with host Dr. Roy Levit the workings of the artificial retina and explains the surgical procedure to implant the device in the eye. The first generation of the implant only has 16 pixels while the second generation has 62 pixels. Dr. Humayun explains how the subjects who have the implant can initially see spots of light, but that the brain over time can fill in the details and many patients are able to see objects, motion and color. At this time, the implants are available only as a part of the clinical trial to subjects who are completely blind as a result of retinitis pigmentosa.
Host: Roy Levit, MD
Dr. Richard Rosen, surgeon director for the department of ophthalmology and director of ophthalmic research in the Advanced Imaging Center at New York Eye and Ear Infirmary, joins host Dr. Roy Levit to discuss technologies and methods to examine the retina.
Host: Roy Levit, MD
Guest: Cliff Ratner, MD
Dr. Roy Levit welcomes Dr. Cliff Ratner to the Revealing Retina. Dr. Ratner did his residency at Harkness Eye Institute and a 2 Year Retina Fellowship at Wilmer Institute at Johns Hopkins. He has been in private practice for 25 years and is the founder of The Retina Practice of White Plains in New York. With his vast experience and expertise, he will talk about how much has changed and is currently changing in the treatment for Wet Macular Degeneration.
Host: Roy Levit, MD
Guest: Paul Tornambe, MD
Dr. Roy Levit welcomes Dr. Paul Tornambe to The Revealing Retina. Dr. Tornambe is in private practice in the San Diego/La Jolla area, and has written over a dozen peer reviewed papers on vitreo retinal disease. He lectures worldwide and is a Journal Referee for the AJO, Archives of Ophthalmology, Retina, British Journal of Ophthalmology, and the German Journal of Ophthalmology. He is a past president of the American Society of Retina Specialists. Dr. Tornambe will discuss the fact that because most residents eventually become board certified, the overall certification rate for the American Board of Ophthalmology (ABO) is not a discriminating educational outcome measure. He will talk about resident performance from program match to certification.
Host: Roy Levit, MD
Guest: David Williams, MD
Dr. Roy Levit welcomes Dr. David F. Williams to The Revealing Retina. Dr. Williams is a Vitreoretinal Specialist practicing in Minneapolis. He is currently Vice President as well as Program Chairman of the ASRS--American Society of Retina Specialists. Dr. Williams will discuss Wet Age-Related Macular Degeneration, also known as Neovascular AMD or Exudative AMD. He will highlight the symptoms and how to make a definitive diagnosis as well as the importance of the location of neovascular lesions as a vital factor affecting the progression of the disease and the risk of vision loss.
Host: Leslie P. Lundt, MD
Guest: Dan Roam
Tremendous leaps have been made in the science of vision giving us a better understanding of how we see. What do visual pathways teach us about the process of visual thinking? Host Dr. Leslie Lundt welcomes Dan Roam, author of The Back of the Napkin: Solving Problems and Selling Ideas with Pictures to discuss how we can use visual thinking techniques to improve our communication skills.
Host: Roy Levit, MD
Guest: Michael Newton, MD
Dr. Roy Levit welcomes Dr. Michael Newton, Medical Ethicist and an Ophthalmologist specializing in corneal disease and transplantation. They will dicuss Dr. Newton's book, "Without Your Consent, The Hijacking of American Health Care". They will cover all of the outside influences from managed care to hospitals to government that are influencing the way MD's practice medicine today.
Host: Roy Levit, MD
Guest: Jerald Bovino, MD
Dr. Roy Levit welcomes Dr. Jerald Bovino to the Revealing Retina. Dr. Bovino is a retired retinal surgeon who is well published in the area of physician retirement. Physician retirement issues will be explored and advice given. Some examples in the retinal field will be cited.
Host: Leslie P. Lundt, MD
Guest: Michael Gordon, MD
Myopia, or near-sightedness, affects approximately 25% of Americans between the ages of 12 and 54. Though glasses are the common quick fix to myopia, laser eye surgery has become more commonly used to correct vision problems since being introduced in the early 1990's. Though over 18 million LASIK procedures have been performed worldwide, some controversy still remains regarding the maximum possible correction and efficacy using this technique. What does the one of the country’s top refractive surgeons have to say? Listen as host Dr. Leslie Lundt interviews one of the most respected eye surgeons in the country, Dr. Michael Gordon.
Host: Paul Raeburn
Guest: Babak Parviz, PhD
Paul Raeburn interviews Dr. Babak Parvis of the University of Washington about putting computers on contact lens. Pie in the Sky? Not if this scientist has anything to do with it.
Host: Maurice Pickard, MD
Guest: Richard King
In his book “My Maggie,” Chicago sports anchor Rich King writes a powerful, complex, and memorable love story about his childhood sweetheart and wife of 32 years. Diagnosed with hearing loss at the age of four, Maggie wore cumbersome hearing aids and felt the humiliation of being "different." Slowly, an insidious disease later diagnosed as Usher Syndrome robbed her of vision. But she soldiered on, having fought three different cancers, changed careers in the middle of her life and fought to realize her dreams. Maggie King confronted this progressive disease with courage and dignity throughout her career in nursing and later as a strong advocate for the disabled.
Host: Larry Kaskel, MD
Guest: Mani Bhaumik, PhD
The excimer laser was the key component to the invention of lasik surgery, responsible to returning nearly perfect vision to millions of people. How was the excimer laser developed and how did it turn into a miracle capable of correcting vision? Join Dr. Larry Kaskel talking with the co-inventor of the excimer laser, Dr. Mani Bhaumik.
Host: Roy Levit, MD
Guest: Julia Haller, MD
Dr. Roy Levit welcomes Dr. Julia Haller to The Revealing Retina. Dr. Haller is President of the American Society of Retina Specialists and Chairman, Wills Eye Hospital, Philadelphia. They will discuss the different types of macular degeneration, the demographics involved and who should be treating it.
Guest: Suber Huang, MD
Tune in to hear the first in a monthly series entitled, "The Revealing Retina". Dr. Roy Levit, host and president of the American Retina Fundation, welcomes Dr. Suber Huang, Director of Vitreoretinal Diseases and Surgery at University Hospitals of Cleveland, and Medical Director and Treasurer for University Ophthalmologists, Inc. to discuss Diabetic Retinopathy, it's cause and effects. Listeners will gain information on how to understand and identify visual changes in their diabetic patients.
Host: Maurice Pickard, MD
Guest: Joel Kaplan, MD
Dr. Maurice Pickard speaks with Dr. Joel Kaplan about the Chicago Lighthouse for People Who are Blind or Visually Impaired, including the institution itself and the various programs it provides. Its members work closely with the visually impaired at all age levels and provide numerous supportive resources for medical and social enrichment.
Host: Michael Greenberg, MD
Guest: Bruce Goldstick, MD
Dr. Michael Greenberg speaks with Dr. Bruce Goldstick about his experience creating a clinic for eye patients in Kiev, Ukraine.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.
Host: Larry Kaskel, MD
Guest: Elise Torczynski, MD
Dr. Elise Torcynski, ophthalmic pathologist, and expert witness in over 20 SBS cases will discuss aspects of the syndrome itself as well as the retinal implications.